long intergenic non-protein coding RNA 1587Genealiases: C4orf6 · aC1
Q-omics provides the consensus-scored LINC01587 profile across patient tissues and cancer cell-line models. LINC01587 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LINC01587 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01587 RNA expression shows 13,406 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, KIRC, and THYM as cancer lineages where LINC01587 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01587 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01587 survival associations across molecular data types. LINC01587 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01587 RNA expression–survival associations across cancer types. High LINC01587 expression shows unfavorable associations in CHOL, LIHC, MESO and LGG, but favorable associations in KIRP and KIRC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for LINC01587 RNA expression.
This table summarizes LINC01587 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LINC01587. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01587 shows lower tumor expression in HNSC and higher tumor expression in KIRC, LUAD, KIRP, LUSC and CHOL. The KIRC box plot shows higher LINC01587 RNA expression in tumor versus normal tissue (log2 FC = +3.316, t-test p < 0.001).
This table shows molecular features associated with LINC01587 in patient tissues and cancer cell lines. In patient samples, LINC01587 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01587 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and NCI60_ALL.
